Objective: To evaluate potential adverse associations of individual antiretroviral medications used in combination antiretroviral therapy regimens on cardiac structure and function in youth with perinatally-acquired HIV infection (PHIV).
Introduction
Perinatally HIV-infected (PHIV) children born early in the HIV epidemic often experienced severe cardiacrelated conditions such as cardiomyopathy, congestive heart failure, and even cardiac-related deaths, but these conditions now rarely occur among those receiving combination antiretroviral therapy (cART) regimens [1] [2] [3] [4] [5] [6] [7] . However, cardiac structure and function in these youth differ subtly from that of youth who are perinatally HIV-exposed but uninfected (PHEU) [7] . These differences may be partially attributable to chronic inflammation, but may also be related to individual antiretroviral medications included in combination regimens [8] . These subclinical differences could lead to symptomatic cardiomyopathy or atherosclerotic heart disease as youth become adults and are exposed to other traditional cardiovascular risk factors such as smoking, obesity, and diabetes [3, 7, [8] [9] [10] .
Several studies have examined the effects of HIV infection and ART on cardiac status in children. The Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study (P 2 C 2 Study) conducted in the era before cART (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) found that increased left ventricular mass and decreased left ventricular contractility were early predictors of mortality in PHIV children [2] [3] [4] 11] . More recently, the Pediatric HIV/ AIDS Cohort Study (PHACS) network measured cardiac structure and function in 325 PHIV and 189 PHEU youth, and compared these measures to those of 70 P 2 C 2 PHIV youth in the same age range [7] . Measures of cardiac function, such as left ventricular fractional shortening and contractility, were significantly and substantially poorer in the P 2 C 2 youth than in the current PHIV and PHEU AMP cohorts. A longer duration of ART was associated with lower fractional shortening in the P 2 C 2 cohort, but not in the more contemporary AMP PHIV cohort, who had typically received cART since infancy [7] . Recent studies clearly demonstrate that the use of cART is associated with better cardiac functioning among PHIV youth [12] .
Despite the cardioprotective effect of cART on today's PHIV youth, the possibility of adverse effects of individual ART drugs on cardiac structure and function has received little attention. Studies in adults with HIV have found that abacavir and protease inhibitors are associated with clinical cardiac outcomes such as myocardial infarction and atherosclerotic heart disease [13] [14] [15] , but these findings are based on very large studies with long-term follow-up and in age groups with higher incidence of cardiovascular events. Several animal and human studies have evaluated effects of zidovudine exposure during pregnancy on cardiotoxicity and cardiac congenital anomalies [16] [17] [18] [19] [20] [21] [22] , but only a few have evaluated zidovudine's effect on cardiac function among cART-treated children and adolescents [5] .
Evaluating the association of individual antiretroviral medications with cardiac outcomes in PHIV youth is complicated by possible drug interactions, and also by the large number of regimens currently used. The standard approach of evaluating individual antiretroviral medications one at a time can be biased because it does not account for other drugs in the same regimen [23] . In addition, analyzing a large number of echocardiographic measures results in multiple statistical comparisons which must be considered when interpreting results. In this study, we applied several novel statistical approaches to detect possible adverse effects of individual antiretroviral medications on echocardiographic measures of cardiac structure and function among PHIV youth enrolled in the PHACS Adolescent Master Protocol (AMP).
Methods

Study population
The PHACS Adolescent Master Protocol is a prospective cohort study conducted at 14 academic research hospitals in the United States and Puerto Rico to evaluate the impact of HIV infection and ART on the development of children with perinatal HIV infection [7] . The AMP study includes both PHIVand PHEU children, aged 7-16 years at enrollment between March 2007 and November 2009. As part of the study, enrolled children had a single echocardiogram conducted between 2008 and 2010. The study protocol was approved by the institutional review board (IRB) of each participating site and the Harvard T.H. Chan School of Public Health, and written informed consent was obtained from each child's parent or legal guardian and assent from older participants as specified by the local IRB.
Our analysis included only the AMP PHIV children, who had generally received many years of cART. Children were excluded if they had congenital cardiac abnormalities, such as a large atrial septal defect or a ventricular septal defect. At each semi-annual AMP study visit, information about participants and their families was gathered through clinical interviews and chart reviews. Health status was ascertained at study entry and at each study visit through physical and laboratory evaluations and chart abstraction, and included growth measures (height, weight, and BMI in kg/m 2 ), CD4 þ cell counts, and HIV-1 RNA viral load measures, and Centers for Disease Control and Prevention (CDC) clinical disease class. Information on ART regimens was obtained since ART initiation, with start and stop dates for each regimen; cARTwas defined as any regimen that included three or more antiretroviral medications from two or more drug classes.
Echocardiographic assessment of cardiac structure and function Trained study staff obtained a single M-mode and twodimensional echocardiogram on each child using a standardized protocol with concurrent blood pressure and heart rate measurements. To improve reliability, all echocardiograms were centrally re-measured at the echocardiographic core laboratory at Boston Children's Hospital. Echocardiographic Z scores were calculated using normative data from an established reference cohort of healthy children from Boston Children's Hospital, with adjustment for age and body surface area as appropriate [24] . Although a large number of echocardiographic parameters were measured, we focused on three primary measures of left ventricular function (ejection fraction, contractility, and fractional shortening), four primary measures of left ventricular structure (left ventricular mass, end-diastolic dimension, end-diastolic posterior wall thickness, and end-systolic wall stress), and four secondary measures of left ventricular structure (left ventricular end-systolic and end-diastolic volumes, end-systolic thickness-to-dimension ratio, and end-diastolic septal thickness). The study was designed to obtain echocardiograms on 500 PHIV and PHEU children to provide 80% power for detecting clinically meaningful differences in mean Z-scores, and echocardiograms were no longer conducted after December 2010, when this target sample size was achieved.
Statistical methods
We summarized ART exposures as the percentage of youth currently exposed and cumulative years of exposure to each antiretroviral medication at echocardiography, and as the percentage of youth receiving certain pairs of antiretroviral medications within their combination regimen.
We utilized several approaches to identify potential associations between ART medications and cardiac echocardiographic measures. We first applied the 'standard' approach of separately evaluating each antiretroviral medication one at a time with each cardiac outcome using linear regression models adjusting for age and BMI Z-score at the time of echocardiogram, and also sex, race, and ethnicity. One set of models was fit for current antiretroviral medications (exposed vs. unexposed) and another for cumulative duration of antiretroviral medications. As noted above, estimated associations for each individual antiretroviral medication may be biased when not accounting for other antiretroviral medications in the same regimen. Thus, we also fit linear regression models simultaneously including all individual antiretroviral medications to reduce such potential bias; these estimates are referred to as 'mutually adjusted' results. Given the large number of statistical comparisons made (for combinations of 18 antiretroviral medications with 11 echocardiographic measures), significance testing was based on controlling the false discovery rate (FDR) using a Benjamini and Liu threshold of 0.10 within each echocardiographic parameter [25, 26] .
A model with so many correlated antiretroviral medication exposures could lead to multicollinearity and unstable estimates with inflated variances; thus, we also used a hierarchical model including fixed effects for each drug class and specifying a random effect for each drug within its corresponding drug class, as described elsewhere [23] . This hierarchical model essentially estimates individual drug effects as the drug class mean plus a deviation for the individual drug, and generally performs better than separate models and mutually adjusted models; in particular, there are fewer falsepositives, and estimates are generally less biased and more precise [23] .
We also evaluated associations between individual antiretroviral medications and cardiac outcomes using approaches that accounted for the strong correlations among the echocardiographic measures and reduced the dimension of outcomes to a smaller set of latent variables. We conducted an exploratory factor analysis to identify correlated clusters of echocardiographic Z-score measures, and then used the resulting standardized factor scores as latent outcomes, again evaluating all individual antiretroviral medications simultaneously in a single model for each latent factor. Factors were selected based on scree plots, eigenvalues, and percentage of explained variance. Before conducting the factor analysis, missing outcome Z-scores for a small percentage of youth were imputed using an expectation-maximization algorithm [27] . As an alternative latent variable approach, we fit separate repeated-measures models for each 'set' of primary echocardiographic outcomes, with an unstructured covariance assumption to account for correlation between different cardiac outcomes measured on the same participant [28] . More specifically, we fit a repeatedmeasures model for the functional echocardiographic parameters including fractional shortening, ejection fraction, and contractility, which assumed a constant effect of each antiretroviral drug on all three parameters, although an effect for outcome was included to allow the background mean z-scores to vary over the three parameters. All antiretroviral drugs were included in a single model. Similarly, we fit a repeated-measures model including left ventricular mass, end-diastolic dimension, and end-systolic volume, assuming a constant effect of each antiretroviral drug on these 'heart size' measures. Last of all, we fit a repeated-measures model for parameters reflecting heart wall stress, including endsystolic wall stress, thickness-to-dimension ratio, enddiastolic wall thickness, and end-diastolic septal thickness.
Finally, sensitivity analyses were conducted to evaluate how estimated associations changed when adjusted for HIV disease severity, including low nadir CD4% (<15%), unsuppressed viral load (>5000 copies/ml) at the time of echocardiography, and prior AIDS diagnosis (CDC class C). Analyses were conducted using SAS (Version 9.4; SAS Institute, Cary, North Carolina, USA), and were based on data submitted as of July 2014. Assumptions of models were examined and verified using standard model diagnostics and influence statistics for mixed effect models [28, 29] .
Results
Participant characteristics and ART exposures
Of the 451 PHIV youth enrolled in the PHACS AMP study, 325 (72%) had an echocardiogram, obtained at a mean (SD) age of 13.0 (2.7) years (range 7.0-18.7). Of these, 47% were male, 66% were non-Hispanic black, and 23% were Hispanic. The youth were relatively healthy at the time of echocardiography, with a median CD4 þ cell count of 693 cells/ml and most having suppressed viral load (69% with viral load <400 copies/ml); however, 25% had a prior AIDS-defining diagnosis (CDC class C). Additional details on this cohort have been reported previously [7] . Youth with echocardiograms were demographically similar to those without echocardiograms (data not shown).
At the time of echocardiography, 88% were receiving cART (69% with a protease inhibitor), and the mean cumulative duration on cART was 8.1 years (Table 1) . A total of 137 different cART regimens were reported at the time of echocardiography. The most common nucleoside reverse transcriptase inhibitors (NRTIs) were lamivudine, zidovudine, tenofovir disoproxil fumarate (TDF), and abacavir. Among non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz was used more often than nevirapine, and ritonavir-boosted lopinavir was the most common protease inhibitor (Table 1) . Commonly used NRTI combinations at the time of echocardiography included zidovudine þ lamivudine (26%), TDF þ emtricitabine (20%), and abacavir þ lamivudine (18%).
Association of combination therapy with cardiac function and structure Current use of cARTwith a protease inhibitor at the time of echocardiogram was associated with significantly higher (better) cardiac function as reflected by ejection fraction, contractility, and fractional shortening, with adjusted mean Z-scores which were higher by 0.25 (P ¼ 0.03), 0.33 (P ¼ 0.01), and 0.28 (P ¼ 0.02), respectively, compared to those not receiving protease inhibitor-based cART. In contrast, the duration of cART use (with or without a protease inhibitor) was not associated with measures of cardiac function. Neither current use nor duration of cART with a protease inhibitor was associated with left ventricular structural measures.
Association of individual antiretroviral drugs with cardiac function and structure After FDR control, models simultaneously evaluating all individual antiretroviral medications revealed no significant association for any individual antiretroviral medications taken at the time of echocardiography with 2340 AIDS 2018, Vol 32 No 16 the three functional cardiac measures (Supplemental Table 1 , http://links.lww.com/QAD/B341). However, youth receiving efavirenz had decreased contractility (adjusted mean difference ¼ À0.40, nominal P ¼ 0.04) as did those receiving lamivudine (adjusted mean difference ¼ À0.32, P ¼ 0.06). In addition, youth receiving lopinavir had improved cardiac function as measured by ejection fraction and fractional shortening, with Z-scores that were 0.28 and 0.29 higher on average, respectively, compared to those not receiving lopinavir (Table 2) . When not accounting for concurrent use of other antiretroviral medications, the association of efavirenz with decreased contractility appeared stronger, with a mean decrease of 0.46 (P ¼ 0.004), whereas lamivudine showed no association (Table 2) ; however, as noted previously, these estimates are likely biased given the lack of control for other antiretroviral medications in the same regimen. The hierarchical modeling approach yielded results similar to those of the mutually adjusted model. The estimates were slightly attenuated (pulled towards drug class means), but the smaller standard errors reflected increased precision (Table 2 ). Cumulative duration of use was not associated with any left ventricular function measure for any individual antiretroviral medication, when adjusting for all antiretroviral medications in the current regimen (Supplemental Table 2 , http://links.lww.com/QAD/B341).
In evaluating primary and secondary measures of cardiac structure (Supplemental Tables 3 and 4 , http://links. lww.com/QAD/B341, respectively), mutually adjusted mean Z-scores for left ventricular end-diastolic dimension and end-systolic wall stress were higher in youth taking zidovudine at the time of echocardiography than ART drugs and cardiac status of PHIV youth Williams et al. 2341 in those not taking zidovudine, with the latter finding meeting the threshold for significance when controlling FDR at the 0.10 level (Table 2 ). In addition, zidovudine was associated with lower adjusted mean Z-scores for thickness-to-dimension ratio. Current use of stavudine was also associated with higher left ventricular endsystolic wall stress. In contrast, efavirenz was associated with lower left ventricular mass and lower end-systolic wall stress, and nevirapine was associated with higher left ventricular end-diastolic dimension. Few associations were observed for cumulative antiretroviral medication durations with structural parameters (Supplemental Tables 5 Latent variable models for multiple measures of cardiac function and structure Three factors were identified which explained 71% of total variance, each with clear intuitive meaning (Fig. 1) . The first factor ('larger heart size') had high factor loadings on left ventricular mass, end-diastolic dimension, and end-systolic volume; the second factor ('lower heart wall stress') had high positive loadings on left ventricular end-diastolic wall thickness, thickness-todimension ratio, and end-diastolic septal thickness, and a negative loading on left ventricular end-systolic wall stress. Lastly, the third factor ('better heart function') had high positive loadings on contractility, ejection fraction, and fractional shortening. Standardized factor scores (mean 0, SD 1) were obtained for each latent factor, and those for lower heart wall stress were reverse-coded to reflect 'higher heart wall stress' for consistency with the adverse direction of larger heart size. Using the standardized heart function factor score as the outcome, lopinavir was associated with improved cardiac function after adjusting for demographic factors and all other antiretroviral medications (Table 3) . Zidovudine was associated with an adjusted mean increase of 0.32 in heart wall stress factor scores, and both zidovudine and nevirapine were associated with higher adjusted heart size factor scores (by 0.36 and 0.44, respectively) as compared to those not receiving these antiretroviral medications. The repeated-measures models for correlated vectors of echocardiographic measures yielded findings similar to the models of a single factor score within each domain. However, despite the fact that the repeated-measures models each considered multiple echocardiographic outcomes simultaneously and accounted for their intercorrelation, SEs were consistently smaller for estimated associations than when modeling each single factor score (Table 3) . Evaluating cART with a protease inhibitor as an overall regimen using the factor scores and a repeated-measures model for latent variables indicated a significant association with higher heart function, but no association with heart size or wall stress, consistent with findings of individual echocardiographic parameters.
AIDS
Sensitivity analyses accounting for HIV disease severity Sensitivity analyses further adjusting the mutually adjusted antiretroviral models for unsuppressed viral load, low nadir CD4%, and CDC class C diagnosis yielded almost identical findings, suggesting little evidence of confounding by indication. For example, the estimated increase in wall stress with zidovudine was 0.59 (SE 0.21, P ¼ 0.004) after adjusting for viral load greater than 5000 copies/ml, as compared to 0.60 before such adjustment; the mean decrease in left ventricular mass with efavirenz exposure was 0.39 (SE 0.17) with additional adjustment for unsuppressed viral load and 0.38 (SE 0.17) without adjustment (data not shown).
Discussion
Combination ART regimens have been linked to improved cardiac health in children with PHIV, with overt symptoms of cardiomyopathy rarely observed in the current era [1] [2] [3] [4] [5] [6] [7] 12] . Despite this success, individual antiretroviral medications could still cause cardiotoxicities, and given the wide range of choices in combination regimens, identifying those with the safest toxicity profile is warranted. However, evaluating individual antiretroviral medications is complicated by their concurrent use with other antiretroviral medications in combination regimens [30] . We used novel statistical techniques to examine associations of individual antiretroviral medications with cardiac function and structure, accounting for other antiretroviral medications taken concurrently and for multiple statistical comparisons resulting from analyzing multiple echocardiographic measures.
Some individual antiretroviral medications showed consistent patterns of associations with separate echocardiographic measures of cardiac structure, specifically, a larger heart size (left ventricular mass, volume, and/or end-diastolic dimension) with use of zidovudine and nevirapine, smaller heart size with efavirenz, and increased left ventricular end-systolic wall stress with ART drugs and cardiac status of PHIV youth Williams et al. 2343 Table 3 . Association of individual antiretroviral medications with latent measures of heart function, wall stress, and size in models mutually adjusting for all other antiretroviral medications.
Better heart function
Larger heart size Higher heart wall stress Antiretroviral drug or regimen All models adjust for all other antiretroviral drugs, along with age, sex, race, ethnicity, and BMI z-score at echocardiogram. Parameter estimates reflect shift in mean z-score for each antiretroviral drug.
Only those antiretroviral drugs with P < 0.10 (indicated in bold) for at least one latent outcome are shown. Repeated-measures models include correlated set of echocardiogram parameters assuming unstructured covariance: for function -ejection fraction, fractional shortening, and contractility; for size -LV mass, ED dimension, ES volume; for stress -ES wall stress, thickness-to-dimension ratio, ED wall thickness, ED septal thickness. cART, combination antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SE, standard error.
zidovudine. Only the association of zidovudine with increased end-systolic wall stress was statistically significant after FDR correction, but the overall pattern across multiple structural measures provided additional support for an association. Fewer associations were observed with separate echocardiographic measures of cardiac function, although youth taking lopinavir had higher left ventricular ejection fraction and fractional shortening, and efavirenz was linked to lower left ventricular contractility before correcting for multiple comparisons. The apparent benefit of lopinavir on left ventricular function was unexpected, and not consistent with adverse associations of protease inhibitor-based regimens on cardiac health noted in adults [13] [14] [15] .
Use of latent variable models for underlying measures of heart function, size, and wall stress reinforced the findings of separate echocardiographic parameters, indicating an adverse association of zidovudine with both larger heart size and higher heart wall stress, and a beneficial association of lopinavir with higher heart function. While shifts in mean z-scores for these antiretroviral drugs were relatively small, even small increases may have implications at the population level in terms of increased prevalence of clinical conditions such as left ventricular hypertrophy or cardiomyopathy. The subclinical differences in cardiac structure observed in this age group could portend future adverse cardiac outcomes as these children become adults, and other cardiometabolic risk factors such as obesity, smoking, hypertension, and hypercholesterolemia become more common [9, 10, 31] . Many of these risk factors are more prevalent in youth with HIV than similarly aged children in the general population [32] [33] [34] [35] , and protease inhibitors, as a drug class, have often been implicated in metabolic risk factors for cardiovascular disease. However, our results more often identified adverse effects with NRTIs and NNRTIs, which may act through other mechanisms such as mitochondrial toxicity. Lopinavir appeared to be protective, and no other protease inhibitors were associated with adverse function or increased heart wall stress or size.
Our observational study of individual antiretroviral effects has certain limitations. We cannot rule out residual confounding, including possible confounding by indication, which could result if children with more severe disease were more likely to be treated with certain medications. Sensitivity analyses controlling for measures of both current and past HIV disease severity produced almost identical results, which suggests that the effect of such confounding is limited. In addition, in the current era, HIV disease severity has not been associated with cardiac structure or function among otherwise healthy and virologically suppressed youth [7] . We used several approaches to limit false-positives, but because we are concerned with the safety profile of antiretroviral medications, we must also consider type II errors (missing true associations). We did not include antiretroviral medications with very rare exposures, including several newer medications, such as dolutegravir, and ones no longer used, such as indinavir and zalcitabine. Continued monitoring is clearly warranted, particularly as newer agents become prescribed more widely.
The strengths of our study include the use of several novel statistical techniques that allowed us to evaluate a large number of individual antiretroviral medications and to reduce multiple cardiac outcomes to manageable number. In addition, our hierarchical approach took advantage of the fact that mechanisms of action are often similar within a single drug class [36] [37] [38] . In this particular evaluation, the hierarchical model provided results similar to those of the mutually adjusted model and offered little additional benefit, but the hierarchical modeling strategy can provide a distinct advantage when considering binary outcomes by ensuring convergence, despite high dimensional exposures [23] . Ideally, a comparative safety evaluation would subject a small number of specific cART regimens in a head-to-head comparison [39] [40] [41] . However, this approach was not feasible here, given that 137 different cART regimens were reported at the time of echocardiography, with the five most common regimens representing only 26% of the total. Nevertheless, further research is warranted for specific combinations of antiretroviral medications including fixed-dose combinations, and also dual NRTI backbones which continue to play a central role in HIV treatment strategies, but have been linked to toxicity across multiple organ systems [42, 43] . The analytic approach described here could be used by investigators evaluating the relationships between large numbers of different antiretroviral medications and combination regimens with adverse outcomes in other organ systems.
In conclusion, we observed beneficial effects of cART regimens which included protease inhibitors on cardiac outcomes in youth with PHIV. However, given the large number of options for specific antiretroviral drugs that can be included in combination regimens, some antiretroviral medications such as zidovudine could be replaced by those with more favorable toxicity profiles. Longitudinal studies are needed to evaluate longer-term trends and early cardiovascular risk factors among youth with HIV to develop targeted interventions for those at highest risk of cardiovascular disease.
